Search

Your search keyword '"Hendifar AE"' showing total 89 results

Search Constraints

Start Over You searched for: Author "Hendifar AE" Remove constraint Author: "Hendifar AE"
89 results on '"Hendifar AE"'

Search Results

4. Ponsegromab for the Treatment of Cancer Cachexia.

5. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.

6. Low booster uptake in cancer patients despite health benefits.

7. Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention.

8. The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analysis Using 2001-2018 United States Cancer Statistics Databases.

9. Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery.

10. Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation Therapy.

11. Recent advances in the management of hepatocellular carcinoma.

12. Socioeconomic disparities in patients with small bowel neuroendocrine tumors.

13. Low booster uptake in cancer patients despite health benefits.

14. Pancreatoblastoma in Elderly Adults: Report of Two Patients.

15. Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol.

18. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).

19. Multitasking dynamic contrast enhanced magnetic resonance imaging can accurately differentiate chronic pancreatitis from pancreatic ductal adenocarcinoma.

20. A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.

21. Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study.

22. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy.

23. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.

24. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.

25. Claudin-18.

26. Chemical Exchange Saturation Transfer for Pancreatic Ductal Adenocarcinoma Evaluation.

28. Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy.

29. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis.

31. Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia.

32. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels.

33. Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience.

34. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors.

35. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan.

36. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177 Lu-DOTATATE.

37. Symptom Management in Pancreatic Cancer.

39. Midgut Neuroendocrine Tumors with Liver-only Metastases: Benefit of Primary Tumor Resection.

40. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.

41. Remote Oncology Care: Review of Current Technology and Future Directions.

42. Priority Rankings of Patient-Reported Outcomes for Pancreatic Ductal Adenocarcinoma: A Comparison of Patient and Physician Perspectives.

43. Novel ALK Fusion, PPFIBP1-ALK , in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib.

44. Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden.

45. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review.

46. Multiparametric Mapping Magnetic Resonance Imaging of Pancreatic Disease.

47. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol.

48. Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.

49. Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations.

50. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients.

Catalog

Books, media, physical & digital resources